Taxane-induced peripheral neuropathy more common in patients with diabetes longer than 5 years
the ONA take:
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for developing severe peripheral sensory neuropathy, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers in Turkey sought to determine whether the presence of diabetes mellitus impacts the incidence and severity of peripheral sensory neuropathy in patients undergoing taxane therapy for cancer. Researchers retrospectively analyzed data from 374 patients receiving taxane therapy at a single institution. Of those, 21.6% had diabetes.
Results showed that the incidence of grade 1 peripheral neuropathy in patients receiving taxane-based therapy was 33.4% in non-diabetics and 25.9% in those with diabetes; however, the incidence of grade 2 or higher peripheral neuropathy was 15% and 34.6%, respectively.
Researchers found that the overall incidence of peripheral neuropathy was 48.8% in non-diabetic patients, 52.8% in patients with diabetes less than 5 years, and 75% in patients with diabetes for longer than 5 years.
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for neuropathy.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|